We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Avian Influenza Virus Shows Pandemic Potential

By LabMedica International staff writers
Posted on 24 Jul 2013
Several qualities that characterize the Chinese H7N9 avian influenza virus suggest to epidemiologists that this strain has the potential to trigger a worldwide flu pandemic.

The recent sporadic infections of humans in China with a previously unrecognized avian Influenza A virus of the H7N9 subtype have caused concern owing to the appreciable case fatality rate associated with these infections (more than 25%), potential instances of human-to-human transmission, and the lack of pre-existing immunity among humans to viruses of this subtype. More...


Investigators at the University of Wisconsin (Madison, USA) and their colleagues at the University of Tokyo (Japan) characterized two early human H7N9 isolates, A/Anhui/1/2013 and A/Shanghai/1/2013.

In mice, Anhui/1 and Shanghai/1 were more pathogenic than a control avian H7N9 virus (A/duck/Gunma/466/2011) and a representative pandemic 2009 H1N1 virus (A/California/4/2009). Anhui/1, Shanghai/1 and Dk/GM466 replicated well in the nasal turbinates (scrolled spongy bones of the nasal passage) of ferrets. Anhui/1 transmitted through respiratory droplets in one of three pairs of ferrets. Ferrets infect one another with influenza virus through coughing and sneezing and are a standard model for studies of influenza in mammals.

In nonhuman primates, Anhui/1 and Dk/GM466 replicated efficiently in the upper and lower respiratory tracts, whereas the replication of conventional human influenza viruses is typically restricted to the upper respiratory tract of infected primates. Anhui/1 was found to be less sensitive in mice to neuraminidase inhibitors than a pandemic H1N1 2009 virus, although both viruses were equally susceptible to an experimental antiviral polymerase inhibitor.

The findings obtained during this study, especially the ability of the virus to replicate in mice, ferrets, and nonhuman primates and the limited transmissibility in ferrets suggest that H7N9 viruses may have pandemic potential.

"H7N9 viruses have several features typically associated with human influenza viruses and therefore possess pandemic potential and need to be monitored closely," said senior author Dr. Yoshihiro Kawaoka, professor of virology at the University of Wisconsin. "H7N9 viruses combine several features of pandemic influenza viruses, that is, their ability to bind to and replicate in human cells and the ability to transmit via respiratory droplets. If H7N9 viruses acquire the ability to transmit efficiently from person to person, a worldwide outbreak is almost certain since humans lack protective immune responses to these types of viruses."

The study was published in the July 10, 2013, online edition of the journal Nature.

Related Links:

University of Wisconsin
University of Tokyo



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.